Drug Profile
Tabalumab - Eli Lilly and Company
Alternative Names: Anti-BAFF MAb; Anti-BAFF monoclonal antibody; LY 2127399Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action B cell activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple myeloma; Multiple sclerosis; Renal failure; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 17 May 2018 Eli Lilly terminates the phase IIIb Illuminate-X trial for Systemic lupus erythematosus in USA, Austria, Hungary, Spain, Latvia, Bulgaria, Italy, the United Kingdom, Germany, and Croatia (NCT01488708)
- 01 Nov 2015 Eli Lilly terminates phase III trial in Systemic lupus erythematosus in USA, South Korea, Mexico and Puerto Rico due to lack of efficacy (NCT02041091)
- 01 Aug 2015 Eli Lilly completes a phase I trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Japan (IV) (NCT01556438)